linjc16/ctgov huggingface dataset:
Monitoring and Characterization of Coronary Flow By Transthoracic Parametric Doppler (TPD) During Exercise Stress Test

Study Overview
=================
Brief Summary
-----------------
The study is an open prospective study of coronary flow preferably of the left anterior descending artery (LAD), by a Transthoracic Parametric Doppler (TPD) system during conventional exercise stress test. The system is a noninvasive non-imaging device designed to monitor coronary flow velocity and display the data continuously during exercise stress tests. The system enables continuous monitoring of coronary flow during resting, stress loading and recovery phases. The study intent is to improve the stress test predictive value for CAD.

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: ultrasound Doppler monitoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or older Planned for ergometry test Signed informed consent Exclusion Criteria: Excluded for stress test on a treadmill

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: ultrasound Doppler monitoring|Ultrasound Doppler monitoring throughout the stress test|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Monitor coronary artery flow during exercise stress test. |  | 1-3 months following the stress test | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improve CAD predictive power of stress testing |  | 1-3 months following the stress test |
A Pilot Evaluation of Adhesives and How They Are Impacted by Output

Study Overview
=================
Brief Summary
-----------------
This study investigates the impact of real output on the adhesion of two adhesives.

Conditions
-----------------
Ileostomy-stoma

Intervention / Treatment
-----------------
* Other: Standard adhesive strip
* Other: New adhesive strip


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have given written informed consent Be at least 18 years of age and have full legal capacity Have had an ileostomy for more than one year Have intact skin on the area used in the evaluation Has an ileostomy with a diameter up to (≤) 35 mm Have a peristomal area accessible for application of patches/adhesive strips (assessed by investigating scientist) - Exclusion Criteria: Currently receiving or have within the past 2 month received radio- and/or chemotherapy Currently receiving or have within the past month received topical steroid treatment in the peristomal skin area or systemic steroid (tablet/injection) treatment. Are pregnant or breastfeeding Having dermatological problems in the peristomal- or abdominal area (assessed by investigating scientist) Participating in other interventional clinical investigations or have previously participated in this evaluation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cohort 3<br>This is a sub-study testing how the adhesion of two adhesives is influenced by exposure to real output. There are two kinds of visits: Visit 1: Two adhesive strips (standard adhesive strip) are applied on the peristomal skin; one strip is exposed to real output (contained in a sleeve) and the other strip is not. Visit 2: Two adhesive strips (new adhesive strip) are applied on the peristomal skin; one strip is exposed to real output (contained in a sleeve) and the other strip is not. Visit 2: | Other: Standard adhesive strip<br>* This is a standard adhesive strip (hydrocolloid)<br>Other: New adhesive strip<br>* This is a newly developed adhesive strip<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peel force | The peel force was measured when the adhesive was removed | 12 hours |
Antegrade Double-J Stent Placement for the Treatment of Malignant Obstructive Uropathy

Study Overview
=================
Brief Summary
-----------------
Ureteral double- J stent is usually inserted by retrograde approach for the treatment of obstructed upper urinary tract. The antegrade approach, can a suitable alternative in certain situations without the need for general or spinal anesthesia. The present study demonstrates the indications, success rate, and complications of this approach in the treatment of malignant obstructive uropathy.

Detailed Description
-----------------
Data of consecutive patients in whom antegrade ureteral stent¬ing was performed between January 2013 and February 2020 were retrospectively analysed using patient records and radiology reports. A total of 174 patients (sexe ratio = 0.51, age range 9-91 years; mean age, 54 years) were included in the study. Ureteral obstruction was caused by bladder cancer (n=92), uterin cancer (n=31), prostate cancer (n=28), colorectal cancer (n= 15) and retroperitoneal tumor (n= 8) (Table 1).

Official Title
-----------------
Antegrade Double-J Stent Placement for the Treatment of Malignant Obstructive Uropathy: a Single Center Experience

Conditions
-----------------
Urologic Neoplasms

Intervention / Treatment
-----------------
* Procedure: Antegrade double-J stent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: malignant uropathy obstruction Exclusion Criteria: benign uropathy obstruction
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| malignant uropathy<br>Antegrade double-J stent | Procedure: Antegrade double-J stent<br>* After exchanging the nephrostomy catheter over the J-tipped guidewire, 5 F multipurpose (45° tip) diagnostic vascular catheter was inserted. Once the pelvi¬ureteric junction was crossed and the ureter accessed, a straight hydrophilic guidewire and a catheter were used. Then, the cath-eter was advanced into the bladder over the wire, this guidewire was exchanged for an ultra-stiff guidewire, an 8 or 10 F double J ureteral stent was placed over the guidewire, and the safety kit of the stent was removed. A final fluoroscopic image was stored for correcting the stent position.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of patient having Antegrade double-J stent placement for the treatment of malignant obstructive uropathy | double j stent placement succeed or failed | 7 years |
Evaluation of Some Prognostic Factors in Acute Aluminum Phosphide Intoxicated Cases

Study Overview
=================
Brief Summary
-----------------
study of some laboratory and clinical findings which may show the severity of aluminium phosphide toxicity and the need of the cases to be admitted to ICU

Detailed Description
-----------------
aluminium phosphide poisoning is a major cause of death in intoxicated and suicidal cases since there is no antidote and there is no specific investigation for it so there is a need for further study to identify the cause of death and the most specific investigation in the case of AlP toxicity

Official Title
-----------------
Evaluation of Some Prognostic Factors in Acute Aluminum Phosphide Intoxicated Cases

Conditions
-----------------
Aluminum Phosphide Poisoning

Intervention / Treatment
-----------------
* Diagnostic Test: some prognostic factors


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: History of exposure or intake of Aluminum phosphide. Clinical picture of Acute Aluminum phosphide poisoning including severe vomiting, hypotension, abdominal pain, cardio-pulmonary distress. Cases of the age of 15 to 45 years old Exclusion Criteria: - 1. Cases with an unclear history. 2. History of co-morbidities or systemic diseases because of the possibility of misleading laboratory results. 3. History of co-ingestion of drugs or another poison.

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| survivors<br> | Diagnostic Test: some prognostic factors<br>* cortisol level, renin, troponin I, MDA ,catalase, super oxide dismutase, liver functions, kidney functions, arterial blood gases, sodium level, potassium level. white blood cells count<br>|
| non survivors<br> | Diagnostic Test: some prognostic factors<br>* cortisol level, renin, troponin I, MDA ,catalase, super oxide dismutase, liver functions, kidney functions, arterial blood gases, sodium level, potassium level. white blood cells count<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prognosis | predict the mortality of intoxicated AlP cases | the first 24 post poisoning |
Assessment of Chilbains Occuring During Covid-19 Infection

Study Overview
=================
Brief Summary
-----------------
Some patients infected by covid-19 develop skin manifestations. These manifestations are still not well known and there pathophysiology remain unclear. Among them, acral manifestation resembling to chilblains appears frequent and quite specific. The aim of this project is to better characterize the cutaneous manifestations occurring during Covid-19 infection with a special focus on chilblains. These acral manifestation could be due to a direct viral effect, but also to microthrombosis or vascularitis. Understanding the pathomechanisms involved could provide interesting clue for understanding not only the skin manifestations but also some of the other systemic symptoms associated to covid-19 infection. This study plan to characterize these acral manifestations by analyzing the clinical and dermoscopic patterns and to correlate them with the non-invasive vascular explorations but also immune and coagulopathy explorations that are done in the CHU of Nice in covid-19 patients.

Official Title
-----------------
Assessment of Skin Manifestations Occuring During Covid-19 Infection With a Special Focus on Chilbains

Conditions
-----------------
Chilblains, COVID, Skin Manifestations

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with proven covid infection (using PCR, serum antibody or lung TDM) and presenting at least one cutaneous lesions that occurred during the infection.

Ages Eligible for Study
-----------------
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical skin manifestations | Type and description of the skin manifestations with a special focus on patients with chilblains | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Histology and biological data | Data on Histology (HE staining and immunofluorescence) and on biology (blood cells counts, CRP and immune profile) will be collected in covid patient with skin manifestation | 3 months | 
| Non invasive vascular examination | Vascular examination will be performed by Capillaroscopy, laser-doppler or lung TDM if clinically required | 3 months |
Ultrasound Guided Femoral Nerve Block Catheter Analgesia Compared With Epidural Analgesia for Patients With Knee OA (Osteoarthritis) Who Underwent Unilateral Total Knee Replacement

Study Overview
=================
Brief Summary
-----------------
Post-operative pain following total knee replacement can be disabling and sometimes lead to the need for prolonged hospital stay. Therefore development of improved post-operative modalities for total knee replacement surgery pain control is important. High-resolution ultrasound (US) allows accurate visualization of nerves and surrounding structures and can lead to higher success rates of nerve block. The investigators aim at comparing the analgesic efficacy of ultrasound-guided nerve block catheter compared with epidural analgesia for patients with knee OA who underwent unilateral total knee replacement.

Conditions
-----------------
Knee Osteoarthritis

Intervention / Treatment
-----------------
* Other: Ultrasound guided femoral nerve block catheter analgesia compared with epidural analgesia for patients with knee OA (osteoarthritis)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male / female, Bilateral or unilateral knee OA (Osteoarthritis), and ASA (American Society of Anesthesiologist classification) 1 and 2. Exclusion Criteria: Bilateral total knee replacement, Revision total knee replacement, previous knee surgery, Rheumatoid Arthritis, Avascular necrosis (AVN) knee, Post traumatic or post infectious OA, ASA3 and 4.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Epidural<br> | Other: Ultrasound guided femoral nerve block catheter analgesia compared with epidural analgesia for patients with knee OA (osteoarthritis)<br> <br> |
| Femoral catheter<br> | Other: Ultrasound guided femoral nerve block catheter analgesia compared with epidural analgesia for patients with knee OA (osteoarthritis)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
comparing the analgesic efficacy of ultrasound-guided nerve block catheter compared with epidural analgesia
Heart Rate Variability During the Menstrual Cycle

Study Overview
=================
Brief Summary
-----------------
In this study, women will be required to wear a chest heart rate monitor and wrist heart rate monitor daily and collect daily early morning urine samples for the duration of one complete menstrual cycle. This will enable comparisons between data collected from the heart rate monitor and hormone analysis in urine samples to be made.

Detailed Description
-----------------
This study is a prospective observational study of women's heart rate and heart rate variability throughout one complete menstrual cycle. A minimum of 10 volunteers aged 18 years of age or over will be recruited via a variety of methods according to the criteria detailed in section 9. They will be required to wear a chest heart rate monitor and wrist heart rate monitor for 1 hour each day, and throughout the night for one menstrual cycle. In addition, a daily early morning urine sample will be collected throughout the study. Urine samples will be returned to SPD on a regular basis for measurement of urinary hormones related to pregnancy and fertility. Data collected via the monitors including heart rate and heart rate variability will be downloaded for comparison.

Official Title
-----------------
Further Investigations of Heart Rate Variability During the Menstrual Cycle

Conditions
-----------------
Ovulation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 18 years of age and over Regular menstrual cycles (23-35 days in length)- Exclusion Criteria: Taking any hormonal medications Taking any medications that may affect heart rate Known heart condition or use of a pacemaker Skin condition where there is sensitivity to wearing a skin monitor Currently suffering with anxiety or panic attacks Pregnant or breastfeeding Undertaking any frequent travel or long-haul flights during the course of the study Does not have access to an Apple iPhone or iPad with Bluetooth 4.0 (or later) and iOS 10.0 (or later)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Heart rate | Heart rate at time points throughout the menstrual cycle | 1 month | 
| Heart Rate | Heart rate variability at time points throughout the menstrual cycle | 1 month | 
| Day of Ovulation | Day of ovulation determined by urinary LH surge +1 day | 1 month | 
| Fertile Window | Fertile window onset determined by E3G surge | 1 month | 
| Fertile window | Fertile window closure determined by P3G rise | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparisons between wrist and chest band monitors | Agreement between wrist band and chest band heart rate data | 1 month |
A Clinical Trial of the Optimal Treatment Period and Long-term Efficacy of Functional Electrical Stimulation (FES) on Sleep Bruxism

Study Overview
=================
Brief Summary
-----------------
To investigate the effect of the treatment with Grindcare® on the parafunction of the muscles- and jaw activity (Bruxism) during sleep.

Conditions
-----------------
Temporomandibular Disorder, Headache

Intervention / Treatment
-----------------
* Device: Grindcare® (Biofeedback)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: RDC-TMD diagnosis Verified sleep bruxism More than 18 Years Signed ICF Exclusion Criteria: Contraindication of concomitant medication and diseases judged by investigator Pacemaker

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Grindcare® (Biofeedback)|Active treatment with functional electrical stimulation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction of number of grinds per hour per night |  | 7 weeks |
Prevention of Functional Decline of Aged Women

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate the capacity of muscular function and articular amplitude in the aged women who participated in the Support Group and its influence on the prevention of function decline of these women.

Detailed Description
-----------------
To evaluate the capacity of muscular function and articular amplitude in the aged women who participated the Support Group and its influence on the prevention of function decline of these women is use the method: It is an interventional and quantitative research. A questionnaire of identification and instruments will use: a) flexion and extension tests of muscular function and articular amplitude of shoulders, elbows, wrists, hip, knees and ankles, in the beginning and in the end of the program b) educational action c) physical exercise d) the check up of the results after the exercises e) two questions to register the influence of the support group in the functional life of the researched ones.

Official Title
-----------------
The Influence of the Support Group on the Functional Incapacity in the Prevention of Functional Decline of Aged Women.

Conditions
-----------------
Health Care Quality, Access, and Evaluation

Intervention / Treatment
-----------------
* Behavioral: Physiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: woman with 60 years old or more Exclusion Criteria: woman with less 60 years old

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: groups of women<br>To evaluate the capacity of muscular function and articular amplitude in the aged women | Behavioral: Physiotherapy<br>* Exercise two days a week for six month<br>* Other names: articular amplitude;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A instrument was used for flexion and extension tests of muscular function and articular amplitude of shoulders, elbows, wrists, hip, knees and ankles, in the beginning and in the end of the program; physical exercise; the check up of the results |  | six month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prevention, Quality of Health Care, Health Care Evaluation Mechanisms